Filing Details

Accession Number:
0000919574-24-001888
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-06 19:20:18
Reporting Period:
2024-03-04
Accepted Time:
2024-03-06 19:20:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1162194 Standard Biotools Inc. LAB Laboratory Analytical Instruments (3826) 770513190
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534260 Casdin Partners Gp, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No Yes No
1534261 Casdin Capital, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No Yes No
1534264 Eli Casdin 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No Yes No
1534265 Casdin Partners Master Fund, L.p. 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No Yes No
1823061 Casdin Private Growth Equity Fund, L.p. 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No No No
1864554 Casdin Private Growth Equity Fund Gp, Llc 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No No No
1891102 Casdin Private Growth Equity Fund Ii, L.p. 1350 Avenue Of The Americas
Suite 2600
New York NY 10019
Yes No No No
1919480 Casdin Private Growth Equity Fund Ii Gp, Llc 1350 Avenue Of The Americas, Suite 2600
New York NY 10019
Yes No No No
1938709 Casdin Partners Fo1-Msv, Lp C/O Casdin Partners Gp, Llc
1350 Avenue Of The Americas, Suite 2600
New York NY 10019
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-04 250,000 $2.57 11,496,525 No 4 P Direct
Common Stock Acquisiton 2024-03-05 1,403 $2.62 11,497,928 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 103,556 Direct
Common Stock 2,744,219 Indirect See footnoe
Common Stock 1,200,000 Indirect See footnoe
Common Stock 7,548,000 Indirect See footnoe
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
  3. The securities are owned directly by Eli Casdin.
  4. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
  5. The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
  6. The securities are owned directly by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings II, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II.